SCHEDULE: Voyager Therapeutics Stake Increased by Armistice Capital

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 5.87% of Voyager Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, indicating their beneficial ownership of 3,500,000 shares of Voyager Therapeutics, Inc. common stock.
• This holding represents 5.87% of the total class of securities.
• The filing is an amendment (Amendment No. 8) and the event date requiring the filing is March 31, 2026.
• Armistice Capital, LLC, organized in Delaware, acts as the investment manager for the Master Fund, which directly holds the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and may be deemed to beneficially own the shares held by the Master Fund.
• The Master Fund, a Cayman Islands exempted company, has the right to receive dividends and proceeds from the sale of these securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of increased ownership by an institutional investor, indicating active investment rather than a specific company performance announcement.

Positives

• Armistice Capital, LLC and Steven Boyd have disclosed a significant ownership stake (5.87%) in Voyager Therapeutics, Inc., suggesting confidence in the company's prospects.
• The filing indicates a structured investment approach through a Master Fund managed by Armistice Capital.

Negatives

• The Master Fund disclaims beneficial ownership of the securities due to its investment management agreement with Armistice Capital, which limits its voting and disposition powers.

Risks

• The filing does not explicitly detail risks associated with the investment or the company's operations. The primary risk is inherent in any equity investment, which is subject to market fluctuations and company-specific performance.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Voyager Therapeutics, Inc. The future outlook for the investment depends on the performance of Voyager Therapeutics, Inc. and the investment strategy of Armistice Capital.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Armistice Capital, LLC and Steven Boyd indicates a significant institutional investor's stake in Voyager Therapeutics, Inc. Such filings are common for investors crossing a 5% ownership threshold and signal active participation or monitoring of the company's strategic direction within the biotechnology sector.

Related Party Transactions

• The relationship between Armistice Capital, LLC (investment manager) and the Master Fund (direct holder of shares) is a related party transaction governed by an Investment Management Agreement.

Stakeholder Impact

• Shareholders of Voyager Therapeutics, Inc.: The increased stake by a significant investor like Armistice Capital may be viewed positively, potentially indicating confidence and influencing market perception.
• Management of Voyager Therapeutics, Inc.: The filing signals that a substantial portion of the company's stock is held by an active investment firm, which may lead to increased engagement or scrutiny.
• Creditors of Voyager Therapeutics, Inc.: While not directly impacted, significant shifts in major shareholdings can indirectly affect a company's financial stability and access to capital.

Next Steps

• Armistice Capital, LLC and Steven Boyd will continue to hold and potentially manage their investment in Voyager Therapeutics, Inc.
• Future amendments to this Schedule 13G will be filed if there are changes in beneficial ownership.

Key Dates

Keywords

Voyager Therapeutics, Schedule 13G, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Investment Management